Interventions for pityriasis rosea

摘要: Background Pityriasis rosea is a scaly, itchy rash that mainly affects young adults and lasts for 2 to 12 weeks. The effects of many available treatments are uncertain. This an update Cochrane Review first published in 2007. Objectives To assess the interventions management pityriasis any individual diagnosed by medical practitioner. Search methods We updated our searches following databases October 2018: Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS. searched five trials registers. also checked reference lists included excluded studies, contacted trial authors, scanned abstracts from major dermatology conference proceedings, CAB Abstracts database. PubMed adverse November 2018. Selection criteria Randomised controlled rosea. Treatment could be given single therapy or combination. Eligible comparators were no treatment, placebo, vehicle only, another active compound, placebo radiation treatment. Data collection analysis used standard methodological procedures expected Cochrane. Our key outcomes good excellent improvement within two weeks, rated separately participant practitioner; serious events; resolution itch weeks (participant-rated); reduction score minor participant-reported events not requiring withdrawal Main results 14 (761 participants). In general, risk selection bias was unclear low, but performance reporting high 21% studies. Participant age ranged 60 years, sex ratio similar. Disease severity measured various indices, which studies did categorise. Six conducted India, three Iran, Philippines, one each Pakistan, USA, China. departments paediatric clinic. Study duration 5 26 months. Three funded drug manufacturers; most report their funding source. assessed macrolide antibiotics, antiviral agent, phototherapy, steroids antihistamine, Chinese medicine. None participant-rated improvement. All reported except effects, throughout There probably difference between oral clarithromycin (risk (RR) 0.84, 95% confidence interval (CI) 0.47 1.52; 1 study, 28 participants) (medical practitioner-rated) (RR 1.13, CI 0.89 1.44; For this comparison, there (1 participants); measured; all evidence moderate quality. When compared with erythromycin may lead increased 4.02, 0.28 56.61; 86 participants, low-quality evidence); however, indicates result compatible benefit little treatments. Itch measured, study score, larger (MD 3.95, 3.37 4.53; 34 moderate-quality evidence). same single, small trial, none participants had event, clear groups events, gastrointestinal upset 2.00, 0.20 20.04; Two azithromycin vitamins. 0.83, 2.48) 0.04, -0.35 0.43) (both based on study; 70 Low-quality 1.02, 0.52 2.00; 119 these reported, specifically mild abdominal pain 5.82, 0.72 47.10; Acyclovir vitamins, treatment (all Based (21 participants), higher than acyclovir 0.34, 0.12 0.94); measured. However, significant favour versus 2.45, 1.33 3 141 either group, (only group experienced diarrhoea). One added care (calamine lotion cetirizine) alone (24 addition 4.50, 1.22 16.62) 1.26, 0.74 1.78) alone. Rash such as headache 7.00, 0.40 122.44) Authors' conclusions leads excellent, practitioner-rated effect inconclusive. found low- reduces more placebo. Small sizes, heterogeneity, blinding selective limited conclusions. Further research needed investigate different dose regimens antivirals